Back

Prospective evaluation of cardiac function in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T therapy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: global clinical challenges Cardio-Oncology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Isamu Sunayama

Hyogo College of Medicine, Nishinomiya (Japan)

6 More presentations in this session

Presentation thumbnail
Elevated remnant cholesterol and increased risk of colorectal cancer and atherosclerotic cardiovascular diseases: a prospective cohort study
Miss Y. Xiao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Effects on cardiotoxicity of CT-P6 Biosimilars vs Trastuzumab among adults with breast cancer: a systematic review and meta-analysis
Doctor F. Santoceldes (Taguig, PH)
Abstract Slides Video
Presentation thumbnail
Effects of chemoradiotherapy on the cardiac and aortic glucose metabolism in patients with advanced non-small cell lung cancer
Doctor P. Khaing (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
Practical value and external validation of the PRECISE-DAPT cancer score in patients with acute myocardial infarction
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
Real-world analysis of risk factors for cardiovascular toxicity associated with immune checkpoint inhibitors
Professor R. Asteggiano (Turin, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: global clinical challenges

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function
thumbnail
Congress Presentation
Cardiovascular implications of CAR-T cell therapy: insights from a regional cardio-oncology program
thumbnail
Congress Presentation
Longitudinal changes of cardiac magnetic resonance parameters in patients with cardiac light-chain amyloidosis receiving anti-plasma cell therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources